These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24884599)

  • 1. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
    Pecori C; Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Sturchio A; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; Mancardi GL; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
    BMC Neurol; 2014 May; 14():114. PubMed ID: 24884599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.
    Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi G; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP
    BMC Neurol; 2012 Oct; 12():124. PubMed ID: 23088447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
    Kaplan S; Dragut CF; Ghimpeteanu A
    Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Zhu F; Zhao Y; van der Kop M; Synnes A; Dahlgren L; Sadovnick AD; Traboulsee A; Tremlett H
    CNS Drugs; 2014 May; 28(5):475-82. PubMed ID: 24643915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Dahlgren L; Sadovnick A; Sayao A; Synnes A; Tremlett H
    Mult Scler; 2012 Apr; 18(4):460-7. PubMed ID: 21914689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis.
    Andersen JB; Sellebjerg F; Magyari M
    Eur J Neurol; 2023 Jan; 30(1):162-171. PubMed ID: 36098960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Portaccio E; Annovazzi P; Ghezzi A; Zaffaroni M; Moiola L; Martinelli V; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Bellantonio P; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
    Neurology; 2018 Mar; 90(10):e823-e831. PubMed ID: 29438046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study.
    Weber-Schoendorfer C; Hoeltzenbein M; Wacker E; Meister R; Schaefer C
    Rheumatology (Oxford); 2014 Apr; 53(4):757-63. PubMed ID: 24369411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.
    Weber-Schoendorfer C; Schaefer C
    Mult Scler; 2009 Sep; 15(9):1037-42. PubMed ID: 19692433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study.
    Cuello JP; Salgado Cámara P; García Domínguez JM; Lozano Ros A; Mas Serrano M; Martínez Ginés ML
    Med Clin (Barc); 2020 Mar; 154(6):214-217. PubMed ID: 31420082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis and pregnancy: a single-centre prospective comparative study.
    Cuello JP; Martínez Ginés ML; Martin Barriga ML; de Andrés C
    Neurologia; 2017 Mar; 32(2):92-98. PubMed ID: 25728948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.
    Lopez-Leon S; Geissbühler Y; Sabidó M; Turkson M; Wahlich C; Morris JK
    J Neurol; 2020 Sep; 267(9):2721-2731. PubMed ID: 32444984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.